Cromoglicic acid

Oral
Mastocytosis
Adult: 200 mg four times daily. May double the dose if effect is not satisfactory within 2-3 wk. Max: 40 mg/kg/day.
Child: 100 mg four times daily. May double the dose if effect is not satisfactory within 2-3 weeks.
Max Dosage: 40 mg/kg/day.
Renal impairment: Dosage adjustment may be needed.
Hepatic impairment: Dosage adjustment may be needed.

Oral
Food allergy
Adult: 200 mg four times daily. May double the dose if effect is not satisfactory within 2-3 wk. Max: 40 mg/kg/day.
Child: 100 mg four times daily. May double the dose if effect is not satisfactory within 2-3 weeks.
Max Dosage: 40 mg/kg/day.
Renal impairment: Dosage adjustment may be needed.
Hepatic impairment: Dosage adjustment may be needed.

Nasal
Allergic rhinitis
Adult: 2.5 or 5 mg of a 2% or 4% soln is admin as drops or spray into each nostril 4 times daily.
Renal impairment: Dosage adjustment may be needed.
Hepatic impairment: Dosage adjustment may be needed.

Inhalation
Asthma prophylaxis
Adult: 20 mg four times daily as dry powder/nebulised soln or 10 mg four times daily as aerosol, increased to 6-8 times daily if necessary, reduced to 5 mg four times daily once asthma has been stabilised. Additional doses may be taken before exercise.
Elderly:
Renal impairment: Dosage adjustment may be needed.
Hepatic impairment: Dosage adjustment may be needed.

Ophthalmic
Allergic conjunctivitis
Adult: Instill 2 drops of a 4% soln 4-6 times daily or apply a 4% oint bid-tid.
Elderly:
Renal impairment: Dosage adjustment may be needed.
Hepatic impairment: Dosage adjustment may be needed.

Hypersensitivity.

Lactation, cardiac arrhythmias, hepatic or renal dysfunction.

Nausea, headache, dizziness, unpleasant taste, joint pain and swelling, skin rashes, aggravation of asthma, pulmonary infiltrates with eosinophilia, urticaria. Bronchospasm, wheezing, cough, nasal congestion and throat irritation following inhalation of dry powder. Intranasal use: Transient irritation of nasal mucosa. Sneezing and epistaxis (occasional). Eye drops: Transient burning and stinging.

Cromoglycic acid inhibits degranulation of mast cells and therefore suppresses the release of histamine, leukotrienes and slow-reacting substance of anaphylaxis.
Absorption: Oral: Poorly absorbed from the GIT with only 1% bioavailability. Inhalation: 8-10% of a dose of fine powd is deposited and rapidly absorbed from the lungs. Intranasal: < 7% of the dose is absorbed. Ophthalmic: 0.03% is absorbed.

Inhalation: Store at 25°C. Nasal: Store at 25°C. Ophthalmic: Store at 25°C. Oral: Store at 25°C.

Antiasthmatic & COPD Preparations / Nasal Decongestants & Other Nasal Preparations / Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories

D11AH03 - cromoglicic acid ; Belongs to the class of agents for atopic dermatitis, excluding corticosteroids. Used in the treatment of atopic dermatitis.
A07EB01 - cromoglicic acid ; Belongs to the class of antiallergic antiinflammatory, excluding corticosteroids. Used in the treatment of intestinal inflammation.
R01AC01 - cromoglicic acid ; Belongs to the class of topical antiallergic preparations, excluding corticosteroids. Used as antiallergic agents.
S01GX01 - cromoglicic acid ; Belongs to the class of other ophthalmologic antiallergics.
R03BC01 - cromoglicic acid ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, antiallergic agents.